Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Express Scripts
Moodys
McKinsey
Harvard Business School

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Vonoprazan

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Vonoprazan?

Vonoprazan is an investigational drug.

There have been 13 clinical trials for Vonoprazan. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Esophagitis, Gastroesophageal Reflux, and Helicobacter Infections. The leading clinical trial sponsors are Takeda, Hamamatsu University, and St. Luke's Medical Center, Philippines.

There are sixteen US patents protecting this investigational drug and one hundred and fifty-one international patents.

Recent Clinical Trials for Vonoprazan
TitleSponsorPhase
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive EsophagitisPhathom Pharmaceuticals, Inc.Phase 3
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm FeaturesSt. Luke's Medical Center, PhilippinesPhase 4
A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori GastritisChangi General HospitalPhase 4

See all Vonoprazan clinical trials

Clinical Trial Summary for Vonoprazan

Top disease conditions for Vonoprazan
Top clinical trial sponsors for Vonoprazan

See all Vonoprazan clinical trials

US Patents for Vonoprazan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vonoprazan   Start Trial 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same Takeda Pharmaceutical Company Limited (Osaka-Shi, JP)   Start Trial
Vonoprazan   Start Trial Proton pump inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Vonoprazan   Start Trial Acid secretion inhibitor Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Vonoprazan   Start Trial 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vonoprazan

Drugname Country Document Number Estimated Expiration Related US Patent
Vonoprazan China 102421753 2029-02-25   Start Trial
Vonoprazan China 104211618 2029-02-25   Start Trial
Vonoprazan China 105524046 2029-02-25   Start Trial
Vonoprazan China 108129374 2029-02-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Baxter
Merck
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.